FDA Approves Breast Cancer Therapy Developed by Pfizer and Arvinas
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: seekingalpha
- New Drug Approval: The FDA approved vepdegestrant, a breast cancer therapy developed by Pfizer and Arvinas, marking a significant new treatment option for late-stage breast cancer patients, which is expected to enhance patient care.
- Significant Efficacy: In the VERITAC-2 Phase 3 clinical trial, patients treated with vepdegestrant experienced a progression-free survival of five months compared to just 2.1 months for those on the established drug fulvestrant, demonstrating the drug's superior efficacy.
- Companion Diagnostic Approved: The FDA also authorized the Guardant360 CDx companion diagnostic device developed by Guardant Health, aimed at identifying breast cancer patients with ESR1 mutations, thereby improving treatment precision and effectiveness.
- Broad Market Potential: This approval not only opens new market opportunities for Pfizer and Arvinas but may also foster further collaboration and innovation in breast cancer treatment, enhancing their competitive position in the biopharmaceutical market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.920
Low
24.00
Averages
28.56
High
35.00
Current: 25.920
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Comparison: Eli Lilly vs. Pfizer
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales growth of 56%, highlighting its strong performance in the weight-loss market.
- Dividend Yield Comparison: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at only 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, posing challenges in attracting income-focused investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, placing it at a competitive disadvantage.
- Future Outlook: Although Pfizer faces multiple challenges, it is actively developing new drugs and plans to conduct 20 major studies in 2026, demonstrating its ongoing efforts in drug development and potential for recovery.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Eli Lilly Sales Surge: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving a remarkable 56% overall sales growth, highlighting its strong position in the weight-loss market.
- Pfizer's Dividend Appeal: Pfizer offers a dividend yield of 6.6%, significantly higher than Eli Lilly's 0.6%, making it more attractive to income-focused investors despite facing challenges such as patent expirations.
- Challenges for Pfizer: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, raising concerns about its future growth.
- R&D Outlook: Despite short-term challenges, Pfizer is conducting 20 major studies on new drug candidates, indicating ongoing investment in drug development, which may enable it to regain growth momentum in the future.
See More
Eli Lilly vs Pfizer: Dividend Yield Comparison
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales gain of 56% for the company, highlighting its strong performance in the weight-loss market.
- Dividend Yield Discrepancy: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at a mere 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, which diminishes its appeal among dividend investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, facing headwinds from disappointing COVID vaccine sales and several profitable drugs losing patent protection, particularly Ibrance and Eliquis, which raises concerns about its future growth prospects.
- R&D Resilience and Risks: Although Pfizer faced setbacks in GLP-1 drug development, it is actively acquiring more promising drug candidates and plans to conduct 20 major new drug studies in 2026, demonstrating its resilience in navigating industry challenges.
See More
Pfizer CFO Transition Raises Market Concerns
- Leadership Change: Pfizer announced that CFO Dave Denton will depart in August, raising investor concerns about the company's 2026 financial guidance and leadership continuity, leading to a 2.74% drop in stock price to $25.21, reflecting market uncertainty about the future.
- Surge in Trading Volume: Pfizer's trading volume reached 67.9 million shares, approximately 85% above its three-month average of 36.6 million shares, indicating heightened market attention to the company's dynamics, which may influence short-term stock price volatility.
- New Product Approvals: Recent approvals of Hympavzi and VEPPANU strengthen Pfizer's long-term pipeline, and while the CFO transition poses short-term challenges, the introduction of new products could support future revenue growth.
- Market Confidence Test: During the CFO transition, investors expect management to provide stable financial guidance to ensure that new products, cost controls, and pipeline execution effectively drive earnings recovery and maintain market confidence.
See More
Pfizer CFO Transition Raises Market Concerns
- CFO Departure Impact: Pfizer announced that CFO Dave Denton will leave in August, raising investor concerns about leadership continuity and the execution of 2026 financial guidance, resulting in a 2.74% drop in stock price to $25.21.
- Surge in Trading Volume: Pfizer's trading volume reached 67.9 million shares today, approximately 85% above its three-month average, indicating heightened market interest in the company's future developments.
- New Product Approvals: Recent approvals of Hympavzi and VEPPANU strengthen Pfizer's long-term pipeline, although the company still faces challenges related to patent expirations and cost-control initiatives in the short term.
- Stability of Financial Guidance: During the CFO transition, investors expect management to provide stable financial guidance to ensure that new products, cost controls, and pipeline execution contribute to earnings recovery.
See More
Pfizer Appoints Interim CFO Amid Leadership Transition
- Executive Departure: Pfizer announced that CFO Dave Denton will resign effective August 15, 2026, to pursue opportunities in the consumer goods sector, with his departure not linked to the company's financial performance, raising concerns about financial stability in the market.
- Interim Appointment: Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, will step in as Interim CFO on August 16, 2026, working alongside Denton during the transition to ensure continuity in financial management.
- Guidance Reaffirmation: In a separate filing, Pfizer reaffirmed its fiscal 2026 guidance, projecting full-year revenues between $59.5 billion and $62.5 billion, with adjusted diluted earnings per share expected to range from $2.80 to $3.00, reflecting the company's confidence in its financial outlook.
- Market Sentiment: Despite a 3% drop in PFE shares due to the executive change, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating ongoing investor confidence in the company's long-term prospects.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales growth of 56%, highlighting its strong performance in the weight-loss market.
- Dividend Yield Comparison: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at only 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, posing challenges in attracting income-focused investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, placing it at a competitive disadvantage.
- Future Outlook: Although Pfizer faces multiple challenges, it is actively developing new drugs and plans to conduct 20 major studies in 2026, demonstrating its ongoing efforts in drug development and potential for recovery.
See More
Market Comparison: Eli Lilly vs. Pfizer
- Eli Lilly Sales Surge: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving a remarkable 56% overall sales growth, highlighting its strong position in the weight-loss market.
- Pfizer's Dividend Appeal: Pfizer offers a dividend yield of 6.6%, significantly higher than Eli Lilly's 0.6%, making it more attractive to income-focused investors despite facing challenges such as patent expirations.
- Challenges for Pfizer: Pfizer's stock has declined by 30% over the past five years, primarily due to disappointing COVID vaccine sales and the impending loss of patent protection for several profitable drugs, raising concerns about its future growth.
- R&D Outlook: Despite short-term challenges, Pfizer is conducting 20 major studies on new drug candidates, indicating ongoing investment in drug development, which may enable it to regain growth momentum in the future.
See More
Eli Lilly vs Pfizer: Dividend Yield Comparison
- Significant Sales Growth: Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound saw sales increase by 125% and 80% respectively in Q1 2026, driving an overall sales gain of 56% for the company, highlighting its strong performance in the weight-loss market.
- Dividend Yield Discrepancy: Despite Eli Lilly's stock price rising over 400% in the past five years, its dividend yield stands at a mere 0.6%, significantly lower than the S&P 500's 1% and Pfizer's 6.6%, which diminishes its appeal among dividend investors.
- Pfizer's Challenges: Pfizer's stock has declined by 30% over the past five years, facing headwinds from disappointing COVID vaccine sales and several profitable drugs losing patent protection, particularly Ibrance and Eliquis, which raises concerns about its future growth prospects.
- R&D Resilience and Risks: Although Pfizer faced setbacks in GLP-1 drug development, it is actively acquiring more promising drug candidates and plans to conduct 20 major new drug studies in 2026, demonstrating its resilience in navigating industry challenges.
See More
Pfizer CFO Transition Raises Market Concerns
- Leadership Change: Pfizer announced that CFO Dave Denton will depart in August, raising investor concerns about the company's 2026 financial guidance and leadership continuity, leading to a 2.74% drop in stock price to $25.21, reflecting market uncertainty about the future.
- Surge in Trading Volume: Pfizer's trading volume reached 67.9 million shares, approximately 85% above its three-month average of 36.6 million shares, indicating heightened market attention to the company's dynamics, which may influence short-term stock price volatility.
- New Product Approvals: Recent approvals of Hympavzi and VEPPANU strengthen Pfizer's long-term pipeline, and while the CFO transition poses short-term challenges, the introduction of new products could support future revenue growth.
- Market Confidence Test: During the CFO transition, investors expect management to provide stable financial guidance to ensure that new products, cost controls, and pipeline execution effectively drive earnings recovery and maintain market confidence.
See More
Pfizer CFO Transition Raises Market Concerns
- CFO Departure Impact: Pfizer announced that CFO Dave Denton will leave in August, raising investor concerns about leadership continuity and the execution of 2026 financial guidance, resulting in a 2.74% drop in stock price to $25.21.
- Surge in Trading Volume: Pfizer's trading volume reached 67.9 million shares today, approximately 85% above its three-month average, indicating heightened market interest in the company's future developments.
- New Product Approvals: Recent approvals of Hympavzi and VEPPANU strengthen Pfizer's long-term pipeline, although the company still faces challenges related to patent expirations and cost-control initiatives in the short term.
- Stability of Financial Guidance: During the CFO transition, investors expect management to provide stable financial guidance to ensure that new products, cost controls, and pipeline execution contribute to earnings recovery.
See More
Pfizer Appoints Interim CFO Amid Leadership Transition
- Executive Departure: Pfizer announced that CFO Dave Denton will resign effective August 15, 2026, to pursue opportunities in the consumer goods sector, with his departure not linked to the company's financial performance, raising concerns about financial stability in the market.
- Interim Appointment: Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, will step in as Interim CFO on August 16, 2026, working alongside Denton during the transition to ensure continuity in financial management.
- Guidance Reaffirmation: In a separate filing, Pfizer reaffirmed its fiscal 2026 guidance, projecting full-year revenues between $59.5 billion and $62.5 billion, with adjusted diluted earnings per share expected to range from $2.80 to $3.00, reflecting the company's confidence in its financial outlook.
- Market Sentiment: Despite a 3% drop in PFE shares due to the executive change, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating ongoing investor confidence in the company's long-term prospects.
See More
